Psoria Shield — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Psoria Shield is a private medical device company commercializing the Enhanced Aurora, a compact, dual-wavelength (311nm NB-UVB and 368nm UVA) phototherapy system. The device leverages advanced LED diode technology to offer a portable, low-maintenance alternative to traditional excimer lasers and mercury lamps, targeting the in-office treatment of chronic skin conditions. The company appears to be in an early-revenue, commercial stage, focusing on direct sales to dermatology clinics. Its value proposition centers on superior portability, ease of use, and a comprehensive warranty.

Dermatology

Technology Platform

Dual-wavelength (311nm NB-UVB & 368nm UVA) LED diode-based targeted phototherapy platform for in-office treatment of skin conditions. Emphasizes portability, precise dosing, low maintenance, and integrated safety features via a touchscreen interface.

Opportunities

The large and growing global prevalence of chronic skin conditions like psoriasis and vitiligo creates a substantial addressable market for in-office phototherapy.

There is a clear niche for a portable, user-friendly, and low-maintenance device that can improve clinic workflow efficiency compared to large, traditional systems.

Potential exists for geographic expansion and future development of a connected or home-use device platform.

Risk Factors

Intense competition from established medical device companies with greater resources and brand loyalty in the dermatology space.

Risk of slow clinical adoption if the LED technology is not perceived as equally efficacious as traditional excimer lasers for all patient types.

Financial vulnerability as a small, private company dependent on commercial sales for sustainability.

Competitive Landscape

Psoria Shield competes in the medical phototherapy device market against companies offering traditional excimer laser systems (e.g., from companies like Ra Medical Systems) and narrowband UVB lamp-based units (e.g., from Daavlin, National Biological Corporation). Its primary competitive differentiation is based on form factor (portability, size, weight), modern user interface (touchscreen), and maintenance claims (LED vs. lamps/lasers), rather than on novel therapeutic mechanisms.

More companies in Drug Delivery & Formulation →More companies in United States →